University Hospital, Strasbourg, France

chru-strasbourg.fr

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

966

Active

259

Phase 3

34

Total enrollment

1,069,668

Pipeline matrix

Showing 40 of 47 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Diclofenac gel—————1
Aromatherapy gel—————1
Sublingual sufentanil 30 µg—————1
Morphine sulfate—————1
Rituximab 200mg/6months—————1
Rituximab 1g/6months—————1
Methotrexate + targeted therapy administration—————1
methotrexate or leflunomide + sulfasalazine + hydroxychloroquine administration—————1
Rituximab—————1
Prothrombin time—————1
Biological collection—————1
Isotretinoin—————1
Control group—————1
Hydrocortisone Hemisuccinate: 200 mg per day.—————1
pediatric, prolonged released melatonin—————1
Methylphenidate immediate release 25mg—————1
Treatment—————1
Dapaglifozin—————1
Spironolactone—————1
Dornase Alfa Inhalant Solution [Pulmozyme]—————1
Placebos—————1
no NSAID—————1
protocol for administering NSAIDs already used in routine care—————1
treatment withdrawal—————1
Usual DMT continuation—————1
• Sivelestat intravenous—————1
NaCl intravenous—————1
Use of antipsychotic treatment with marketing authorization at doses lower than those recommended: - Olanzapine - Zuclopenthixol - Risperidone - Pipotiazine palmitate / Pipotiazine - Quetiapine - Flup—————1
- Melatonin - Active light ttherapy—————1
- Placebo drug - Placebo light therapy—————1
Trametinib—————1
Vinblastine—————1
Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for—————1
The retrospective analyses planned for these samples consist of serological analysis and molecular analysis (RT-PCR ) according to the date of symptoms ons—————1
Chemotherapy drug—————1
An additional volume of blood will be drawn as part of routine follow-up care—————1
genetic analysis—————1
Prothrombin—————1
Cladribine—————1
Blood draw, Urine draw—————1
7 more active programs hidden

Next readouts

  • 2020-01
  • 2022-02-23
  • 2024-12-14
  • 2025-02
  • 2025-05-27
  • 2025-06
  • 2025-08-01
  • 2025-10-12
  • 2025-12
  • 2026-03

Top conditions

  • Schizophrenia18
  • COVID-1916
  • Covid-1912
  • Breast Cancer7
  • Septic Shock7
  • Multiple Sclerosis7
  • Rheumatoid Arthritis6
  • Palliative Care6

Frequently asked questions about University Hospital, Strasbourg, France

How many clinical trials does University Hospital, Strasbourg, France have on ClinicalTrials.gov?
University Hospital, Strasbourg, France is listed as the lead sponsor on 966 clinical trials in ClinicalTrials.gov, 259 of which are currently active (recruiting, enrolling, or ongoing).
How many of University Hospital, Strasbourg, France's trials are in Phase 3?
34 of University Hospital, Strasbourg, France's trials are in Phase 3, spread across 47 active drug programs.
What therapeutic areas does University Hospital, Strasbourg, France focus on?
University Hospital, Strasbourg, France's most-studied conditions on ClinicalTrials.gov are Schizophrenia, COVID-19, Covid-19, Breast Cancer, Septic Shock.
When are University Hospital, Strasbourg, France's next clinical trial readouts?
University Hospital, Strasbourg, France has 10 upcoming primary-completion readouts tracked here; the soonest is “Study of the Pathogenicity and Humoral Immune Response Induced by BK Virus in Lung Transplant Recipients”, expected around 2020-01.